TP53 and breast carcinoma: To test this hypothesis, we assessed cell growth and apoptosis upon single- and dual-silencing of GATA3 and MDM2 in the ER-positive, GATA3-wild-type, TP53-mutant (p.L194F) T-47D breast cancer cell line (Supplementary Fig. 4a).